Marker Therapeutics, Inc. MRKR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Marker Therapeutics, Inc. (MRKR) is a healthcare company listed in the US with a market value of about $15M. In fiscal year 2025 it had revenue of $4M and net income of -$12M, a net margin of -343.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 48% a year, a 5-year average ROIC of -64%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 82% below the current price.
About Marker Therapeutics
Marker Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $183064 in 2017 to $4M in 2025, growth of about 44.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 83% over three years (dilution for shareholders). It spends 333% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $7M | $3M | $4M | $0 | $500000 | $213194 | $205994 | $183064 | — |
| Net income | -$12M | -$11M | -$8M | -$30M | -$42M | -$29M | -$21M | -$148M | -$11M | -$2M |
| Free cash flow | — | — | — | — | — | — | -$19M | -$15M | -$8M | — |
| EPS (diluted) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-6.10 | $-4.70 | $-77.50 | $-11.60 | $-7.20 |
| Net margin | -343.0% | -162.8% | -248.8% | -851.9% | — | -5741.2% | -10050.9% | -71826.3% | -5999.1% | — |
| ROIC | -76.6% | -47.3% | -82.0% | -57.4% | -55.8% | -57.6% | -39.9% | -195.1% | -247.6% | -108.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Marker Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 82% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Marker Therapeutics pay a dividend?
Not currently.
Is Marker Therapeutics a good stock to buy?
We do not give buy or sell advice. Marker Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.